Imagine 4 new anticancer drugs Pallituzumab, Geriatriximab, Symptomab, & Exercizumab hit the market. They should dominate the plenary sessions at ASCO & command billion-dollar revenue. But they don't because they're nonpharmacologic & shame on us. Read our opinion piece in @JCO_ASCO ascopubs.org/doi/full/10.120…

Almost game time. Retweet for #KnicksIn5!

A 20-point deficit means NOTHING to the Knicks 😤

Cast of Laocoön and his Sons (Roman version of a lost Greek original), 100BC-50AD

KNICKS!

I'm excited to host @OncLive State of the Science Summit in Philadelphia - with a focus on Breast Cancer. We have put together an excellent faculty & would love to have you join us if you are in the area - registration.onclive.com/sta…

There have been other study in the past in bone mets with different tumors. Same results. We use 3m periodicity since a long time.

Wow, #Asco26 discussant Julie Brahmer is distinctly restrained (OK, scathing!) in her enthusiasm for Harmoni-6 $SMMT

What I appreciate most about this trial is the # of older adults enrolled >50% above age 65 @EileenMOReilly

#ASCO26: Using the Collaborative Care Model to address #mentalhealth care disparities in community #oncology clinics showed meaningful decreases in depressive symptoms. Ft. PC3I Program Director @ramsedhom @ASCO #ASCO asco.org/abstracts-presentat…

Deep inner suffering inevitably arises when the human person is reduced to performance, consumption, or a statistical datum. Many young people today live under the yoke of expectations to perform, immersed in an exasperated competitiveness that generates anxiety, fear of not measuring up, and disorientation.

A really thought-provoking study at #ASCO26 (Abstr 4512, Clinical Science Symposium): decision regret after adjuvant pembrolizumab in RCC. 🔹 The question Do patients regret receiving adjuvant pembro — and if so, is it driven by long-term toxicity that CTCAE grading doesn't adequately reflect? They built a patient co-designed tool focused on long-term toxicity. 🔹 The study 104 RCC pts post-adjuvant pembro across 3 London centres, median f/u 30 mo. Pts completed the Ottawa Decision Regret Scale alongside their own rating of irAEs as life-changing, significant, or non-significant. 🔹 What they found 28% rated their toxicity as significant and 11% as life-changing — but these ratings did NOT correlate with CTCAE grade (a third of G1–2 events were rated significant), and regret was identical for G1–2 vs G3–4 irAEs. Regret was driven by patient-perceived long-term toxicity, especially permanent endocrine and MSK irAEs — and not by disease recurrence (only 1/14 who relapsed expressed regret). Lower baseline expectations of toxicity → more regret. 🔹 My take Striking that >1 in 4 reported significant and >1 in 10 life-changing toxicity. What concerns me most isn't that CTCAE missed these events — it's that the grade didn't correlate with how significant patients found them, nor with regret at all. That deviates from the very purpose of grading. The hard part: a regret analysis is tough to contextualize when the alternative, no treatment, risks recurrence — arguably worse than a long-term toxicity. Adjuvant therapy is challenging by nature: most patients are either cured already or destined to recur regardless — we expose everyone to toxicity to benefit a minority. We urgently need biomarkers to find the few who truly benefit. This slide from @Prof_IanD says it all 👇 Looking forward to seeing the presentation! 🔗 asco.org/abstracts-presentat… #kcsm #ASCO26 @BethN01 @tompowles1

Our own @ramsedhom discussed how embedded psychosocial care in oncology may improve access, engagement, and emotional support during cancer care, as his team has seen with the new Psychosocial Oncology Clinic at @PrincetonHealth. @cure_today spr.ly/6016BBAl0n

Congrats @laurasenamd for publishing the definitive study on IDH1-altered prostate cancers. This is a distinct molecular subtype of PCa with novel therapeutic implications (vorasidenib?). @neerajaiims @VanAllenLab @nikolausschultz europeanurology.com/action/s…

Helpful reflections on the POSITIVE trial - summary - premenopausal hormone receptor–positive patients could be safely treated for their cancer while pursuing family goals ascopost.com/issues/april-25…

“Speak to your children as if they are the wisest, kindest, most beautiful and magical humans on earth, for what they believe is what they will become.”

New study: LLMs identified geriatric assessment domains in EHR notes of older adults with advanced cancer with low false evidence rates @JGeriOnc @WilliamDale_MD sciencedirect.com/science/ar…

We have the evidence We have the tools We have the guidelines But adoption is still low As @WilliamDale_MD noted: the next challenge isn’t discovery, it’s implementation @PallOncCoP @realbowtiedoc @JamesFanWu @FionnualaCrowle @Chaosdyna @jillfeldman4 @DarcyBurbage @ramsedhom

Alliance Trial - duloxetine does not prevent oxaliplatin induced peripheral neuropathy ascopubs.org/doi/10.1200/OA-…

Communication is an intervention. For older adults w/ cancer, the 1st visit & major turning points — progression, hospitalization, decline — are mission critical. journals.sagepub.com/doi/10.…

Outside my usual scope of cancer - but what a beautiful message in this podcast from ⁦@PennMedicine⁩ Memory Center podcasts.apple.com/us/podcas…